Reported Saturday, Gilead Sciences Announced That The Investigational Seladelpar Shows Significant Improvements In Liver Disease Progression And Itch Reduction In Primary Biliary Cholangitis
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences announced that their investigational drug Seladelpar shows significant improvements in liver disease progression and itch reduction in primary biliary cholangitis. 70% of patients receiving Seladelpar 10mg achieved a clinically meaningful composite endpoint, and 37% achieved ALP normalization at 12 months. The reduction in patient-reported pruritus was rapid and durable.
May 20, 2024 | 5:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead Sciences' investigational drug Seladelpar shows significant improvements in liver disease progression and itch reduction in primary biliary cholangitis. Positive interim results are consistent with Phase 3 RESPONSE study.
The positive interim results for Seladelpar, showing significant improvements in liver disease progression and itch reduction, are likely to boost investor confidence in Gilead Sciences. The consistency with Phase 3 RESPONSE study results further strengthens the credibility of these findings, potentially leading to a positive short-term impact on GILD's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100